Navigation Links
Exelixis Announces Third Quarter 2007 Financial Results and Business Update
Date:11/5/2007

tended by one year our research collaboration with Bristol-Myers

Squibb (BMS) to develop and commercialize novel therapies targeted

against the Liver X Receptor. As a result of the extension, we expect

to receive additional research funding in the amount of $7.5 million.

BMS also has the option to extend the collaboration by an additional

year.

* Our wholly-owned subsidiaries Exelixis Plant Sciences, Inc. and

Agrinomics, LLC entered into a transaction with Agrigenetics, Inc., a

wholly-owned subsidiary of The Dow Chemical Company, which included

the sale of tangible and intangible assets and a research funding

agreement focused on the development of new tools for gene discovery

and validation of novel crop traits.

* We closed a public equity offering of seven million shares of common

stock, with net proceeds of approximately $71.9 million, after

deducting offering expenses.

Recent Developments

We presented phase 2 data for XL647 and XL880, and phase 1 data for XL184, XL765 and XL147 at the 2007 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in San Francisco. In total, 13 abstracts were accepted for poster presentation at the conference, reporting data from clinical trials or preclinical studies of XL880, XL647, XL184, XL147, XL765, XL820, XL844 and XL518.

We also announced that a recently completed phase 2 trial of XL784 did not meet its primary endpoint of reducing proteinuria compared with placebo in patients with proteinuria associated with diabetic nephropathy. Various subgroup analyses suggest that the compound may have potential to benefit patients with this disease. We submitted the XL784 data report to GSK on October 22, 2007 and GSK has 90 days from the date of submission of the data report to determine whether it will select XL784 for further clinical development and
'/>"/>

SOURCE Exelixis, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Dow AgroSciences and Exelixis Plant Sciences Announce Major Research Collaboration, Asset Purchase to Advance Gene Discovery and Validation
2. Exelixis Reports Encouraging Interim Data From a Phase 2 Trial of XL647 as First-Line Therapy for Non-Small Cell Lung Cancer
3. Exelixis Announces Closing of Public Offering of Common Stock
4. Exelixis Submits XL880 Diligence Report to GlaxoSmithKline
5. Exelixis Announces November 5 Webcast of its 2007 Third Quarter Financial Results Conference Call
6. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
7. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
8. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
9. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
10. Carrington Announces Nasdaq Communication; Prepares for Shares to Be Quoted on the OTC Bulletin Board and Pink Sheets
11. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... PNAS (Proceedings of the National Academy of Sciences) ... deprivation have a significant effect on our metabolism. The ... time of day to test for diseases such as ... , Researchers from the University of Surrey and The ... sleep deprivation, body clock disruption and metabolism, and discovered ...
(Date:7/10/2014)... forever. Nanophysics makes sure of that. Mechanics researchers at Linkping ... Physical Review E . Knowledge that can be of ... be able to sit still forever, and walk around upside ... soon be able to buy smart new fasteners that hold ... is, sooner or later the grip is lost, no matter ...
(Date:1/15/2014)... assembling a club sandwich at the nanoscale, National ... succeeded in crafting a uniform, multi-walled carbon-nanotube-based coating ... used in upholstered furniture and other soft furnishings. ... was reduced 35 percent compared with untreated foam. ...
(Date:1/15/2014)... Jan. 15, 2014   Niagara Thermal Products is ... Buffalo BioBlower Technologies LLC ("B3") as the critical thermal ... award from the Army Corps of Engineers.  B3 has ... all biological contaminants and destroys VOCs and other chemical ...
Breaking Biology Technology:Time of day crucial to accurately test for diseases, new research finds 2Even geckos can lose their grip 2Layered security: Carbon nanotubes promise improved flame-resistant coating 2Niagara Thermal Products LLC Selected as Critical Supplier for Buffalo BioBlower Air Purification Systems 2
... from Phase II Study Shows 71% Objective Tumor Response Rate ... , - Secondary Endpoint Evaluation Shows Promising 7.4 Month Median ... , ORLANDO, Fla. and TUSTIN, Calif., June 1 Peregrine ... preliminary results from a Phase II trial of its lead ...
... UCB, Inc. and the Crohn,s Disease Working Group (CDWG) today ... Inflammatory Bowel Disease (IBD) for Gastroenterology (GI) Fellows, who each ... or basic research, totaling $175,000 for all four grants. The ... awards were funded by a grant from UCB. A ...
... Therapeutics announced today that promising results from ongoing clinical studies ... presented on AT-101, an oral, pan-Bcl-2 inhibitor, at the 2009 ... 2, in Orlando, Florida. , , (Logo: ... , , "We are delighted with the depth ...
Cached Biology Technology:Peregrine Pharmaceuticals Presents Promising Data From Its Phase II Bavituximab Breast Cancer Trial at 2009 ASCO Annual Meeting 2Peregrine Pharmaceuticals Presents Promising Data From Its Phase II Bavituximab Breast Cancer Trial at 2009 ASCO Annual Meeting 3Peregrine Pharmaceuticals Presents Promising Data From Its Phase II Bavituximab Breast Cancer Trial at 2009 ASCO Annual Meeting 4Peregrine Pharmaceuticals Presents Promising Data From Its Phase II Bavituximab Breast Cancer Trial at 2009 ASCO Annual Meeting 5Peregrine Pharmaceuticals Presents Promising Data From Its Phase II Bavituximab Breast Cancer Trial at 2009 ASCO Annual Meeting 6UCB and Crohn's Disease Working Group Award $175,000 in Research Grants to Gastroenterology Fellows 2Ascenta Therapeutics Announces Presentation of Promising Results From Clinical Trials of AT-101 in Prostate, Brain, and Lung Cancers at 2009 ASCO Annual Meeting 2Ascenta Therapeutics Announces Presentation of Promising Results From Clinical Trials of AT-101 in Prostate, Brain, and Lung Cancers at 2009 ASCO Annual Meeting 3Ascenta Therapeutics Announces Presentation of Promising Results From Clinical Trials of AT-101 in Prostate, Brain, and Lung Cancers at 2009 ASCO Annual Meeting 4Ascenta Therapeutics Announces Presentation of Promising Results From Clinical Trials of AT-101 in Prostate, Brain, and Lung Cancers at 2009 ASCO Annual Meeting 5
(Date:7/10/2014)... Institute for Basic Science (IBS), the main organization of ... Korea, has announced that a group of researchers, led ... technology in the field of optogenetics that can remotely ... new technology "OptoTrk" and it has succeeded with neuronal ... technology is that it requires only light to activate ...
(Date:7/10/2014)... soap might not be ape friendly, and the situation appears ... the Cell Press journal Current Biology on July ... led to the conversion of Southeast Asian forest into oil ... are not put in place very soon, researchers say the ... will be bad news for great apes there as well. ...
(Date:7/10/2014)... Imagine the open ocean as a microbial megacity, teeming ... drop of water, hundreds of types of bacteria can ... of these ocean microbes have their own daily cyclesnot ... to wake up, commute, work, and eat at the ... sun. Light-loving photoautotrophsbacteria that need solar energy to help ...
Breaking Biology News(10 mins):New optogenetic tool for controlling neuronal signalling by blue light 2Hunger for vegetable oil means trouble for Africa's great apes 2New research finds ocean's most abundant organisms have clear daily cycles 2New research finds ocean's most abundant organisms have clear daily cycles 3
... Pop Quiz: what creatures make up more than 70% ... and have long served as model organisms in many ... To begin exploring this question, a new ... was formed and held its inaugural workshop at Nova ...
... are sensitive to social influences but they maintain their ... to what the majority of group members are doing. ... obtain greater rewards, MPI researchers found. ... a rich palette of learning behaviour, both individually and ...
... (UH) Case Medical Center Seidman Cancer Center and Case ... how changes in the genetic composition of breast cancer ... chemotherapy can predict future clinical outcomes in patients. ... reduction in the most commonly mutated genes in breast ...
Cached Biology News:New organization brings together top researchers to sequence genomes of invertebrates 2New organization brings together top researchers to sequence genomes of invertebrates 3Chimpanzees are rational, not conformists 2Deep sequencing of breast cancer tumors to predict clinical outcomes after single dose of therapy 2
...
Jak3 Antibody Ship: Hot Store: -20 C...
WASF2 Immunogen: WASF2 (NP_008921, 73 a.a. ~ 173 a.a) partial recombinant protein with GST tag. Storage: -20 C, Avoid Freeze/Thaw Cycles *Available for distribution in the US only...
Applications: Western blotting Stability: Room temperature, indefinitely ...
Biology Products: